Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.43 |
| ▸ | PPARA | Q07869 | 13/20 | 0.43 |
| ▸ | PPARD | Q03181 | 9/20 | 0.43 |
| ▸ | CMA1 | P23946 | 4/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508324 | 1.00 | PPARG (0.43) | PPARGPPARAPPARDCMA1PTGES | |
| SCHEMBL13508325 | 0.93 | CMA1 (0.37) | PPARGPPARAPPARDCMA1PTGES | |
| SCHEMBL3693308 | 0.93 | CMA1 (0.37) | PPARGPPARAPPARDCMA1PTGES | |
| SCHEMBL13509514 | 0.90 | CMA1 (0.40) | PPARGPPARAPPARDCMA1PTGES | |
| SCHEMBL3684613 | 0.78 | PPARG (0.34) | PPARGPPARAPPARDCMA1 | |
| SCHEMBL3686749 | 0.77 | PPARG (0.43) | PPARGPPARAPPARDCMA1 | |
| SCHEMBL13509470 | 0.77 | CMA1 (0.34) | PPARGPPARACMA1 | |
| SCHEMBL3686996 | 0.77 | CMA1 (0.37) | PPARGPPARAPPARDCMA1 | |
| SCHEMBL13508598 | 0.77 | CMA1 (0.43) | CMA1 | |
| SCHEMBL3689003 | 0.76 | CMA1 (0.42) | CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.